Exploring the comparative efficacy of booster vaccines against SARS-CoV-2 Omicron and Delta variants

NewsGuard 100/100 Score

A recent study posted to the medRxiv* preprint server assessed the effectiveness of vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron and Delta variants.

Study: Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants. Image Credit: Studio Romantic/ShutterstockStudy: Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants. Image Credit: Studio Romantic/Shutterstock

Since the emergence of the SARS-CoV-2 Omicron variant in November 2021, global coronavirus disease 2019 (COVID-19) infections have sharply increased at an unprecedented rate. This novel variant, classified as a variant of concern (VOC) by the World Health Organization (WHO), contains over 30 mutations that impart increased transmissibility and immune-evasive traits.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Omicron vaccine breakthrough cases and reinfections have been observed in many countries raising concerns over the efficacy of available vaccines and therapeutics against the new variant. Studies have reported reduced efficacy of the BNT162b2, mRNA-1273, and ChAdOx1 vaccines against the Omicron variant; however, boosting the immune responses with an additional vaccine dose increased neutralization.

The study

In the present study, the authors measured the efficacy of primary and booster vaccinations against the SARS-CoV-2 Omicron and Delta VOCs and compared the cycle threshold (Ct) values for the two variants in infected cases according to the vaccination status.

The study was conducted in Portugal between December 6 and 26, 2021, when the Delta VOC was predominant in circulation and was gradually replaced by the Omicron VOC. The study population included Portuguese residents aged 12 years or older without a history of COVID-19 infection. People over 50 were included for assessing the effect of booster shots because the younger population was ineligible for boosters.

The Omicron variant is detected based on an S-gene target failure (SGTF) signal in reverse transcription-polymerase chain reaction (RT-PCR) tests due to the Δ69-70 deletion in its spike protein that differentiates it from the Delta VOC. The authors identified Omicron infections by whole genome sequencing (WGS) and/or by SGTF, and all SGTF-positive samples were considered as Delta variants.

In Portugal, two-dose vaccines like BNT162b2, mRNA-1273, ChAdOx1, and Janssen’s single-dose vaccine are used for primary vaccination, and BNT162b2 and mRNA-1273 vaccines are used for booster doses. The vaccination status of the infected cases was stratified as 1) unvaccinated, 2) partial primary vaccination where the COVID-19 diagnosis (vaccine breakthrough infection) was confirmed within 14 days of completion of the vaccine course (two-dose or single-dose), 3) complete primary vaccination with COVID-19 diagnosis after 14 days of the vaccine course, 4) partial boost where vaccine-boosted people were infected with COVID-19 in less than 14 days, and 5) complete boost where the COVID-19 infection was diagnosed after 14 days of administering the booster.

A chi-square test was used to compare the patient characteristics of the Omicron and Delta infections and a logistic regression analysis was used to measure confounding-adjusted odds of complete/booster vaccination. Odds ratio (OR) was calculated and an OR value of 1 indicated no difference in the odds of vaccination, an OR < 1 meant comparatively higher vaccine efficacy against the Omicron VOC than the Delta VOC, and an OR value > 1 is indicative of lower vaccination efficacy against the Omicron variant as compared to the Delta variant.

Findings

A total of 13,134 out of 15,001 collected samples were examined with Omicron cases representing 37.3% of the samples. The authors observed an OR value of 2.1 for mRNA and viral-vectored vaccines in the study population indicating lower vaccine efficacy against the Omicron variant. Around 3,737 of the participants had received booster shots and a higher OR value of 5.2 was observed for boosted individuals infected with the Omicron variant, suggesting lower effectiveness of the booster shots against Omicron compared to the Delta variant.

The researchers estimated the efficacy of vaccines against Omicron infection to be 28.1% for primary vaccination and 68.8% for the booster dose. The mean Ct value for Omicron cases ranged from 18.3 to 18.6 for different vaccines while it was between 17.8 to 19.5 for Delta infections, and these observed differences were not statistically significant.

Conclusions

Based on the above observations, the authors concluded that primary vaccination offered lower protection against the Omicron variant but the vaccine efficacy against the Omicron VOC increased after a booster shot. It is unclear whether the immunity offered by a booster could wane over time as has been observed for primary vaccination and more research is required to monitor the immune responses after the booster dose. The differences noted for Ct values between Delta and Omicron cases were not significant suggesting that the molecular basis for high transmission of Omicron was due to its mutational pattern rather than higher viral load.

To summarize, the study findings revealed that protection by primary or booster vaccination was lower against the Omicron variant as compared to the Delta variant; nonetheless, booster doses offered higher protection than primary vaccination alone. Therefore, in regions where Omicron cases are dominant, booster vaccine doses could help lower the number of COVID-19 infections and reduce the clinical severity of the disease.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:
  • Preliminary scientific report. Irina Kislaya, ANDRE PERALTA SANTOS, Vitor Borges, Luís Vieira, Carlos Sousa, Bibiana Ferreira, Ana Pelerito, João Paulo Gomes, Pedro Pinto Leite, Baltazar Nunes. (2022). Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants. medRxiv. doi: https://doi.org/10.1101/2022.01.31.22270200 https://www.medrxiv.org/content/10.1101/2022.01.31.22270200v1
  • Peer reviewed and published scientific report. Kislaya, Irina, André Peralta‐Santos, Vítor Borges, Luís Vieira, Carlos Sousa, Bibiana Ferreira, Ana Pelerito, et al. 2023. “Comparative Complete Scheme and Booster Effectiveness of COVID‐19 Vaccines in Preventing SARS‐CoV‐2 Infections with SARS‐CoV‐2 Omicron (BA.1) and Delta (B.1.617.2) Variants: A Case–Case Study Based on Electronic Health Records.” Influenza and Other Respiratory Viruses 17 (3). https://doi.org/10.1111/irv.13121https://onlinelibrary.wiley.com/doi/full/10.1111/irv.13121.

Article Revisions

  • May 11 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Tarun Sai Lomte

Written by

Tarun Sai Lomte

Tarun is a writer based in Hyderabad, India. He has a Master’s degree in Biotechnology from the University of Hyderabad and is enthusiastic about scientific research. He enjoys reading research papers and literature reviews and is passionate about writing.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sai Lomte, Tarun. (2023, May 11). Exploring the comparative efficacy of booster vaccines against SARS-CoV-2 Omicron and Delta variants. News-Medical. Retrieved on May 28, 2024 from https://www.news-medical.net/news/20220204/Exploring-the-comparative-efficacy-of-booster-vaccines-against-SARS-CoV-2-Omicron-and-Delta-variants.aspx.

  • MLA

    Sai Lomte, Tarun. "Exploring the comparative efficacy of booster vaccines against SARS-CoV-2 Omicron and Delta variants". News-Medical. 28 May 2024. <https://www.news-medical.net/news/20220204/Exploring-the-comparative-efficacy-of-booster-vaccines-against-SARS-CoV-2-Omicron-and-Delta-variants.aspx>.

  • Chicago

    Sai Lomte, Tarun. "Exploring the comparative efficacy of booster vaccines against SARS-CoV-2 Omicron and Delta variants". News-Medical. https://www.news-medical.net/news/20220204/Exploring-the-comparative-efficacy-of-booster-vaccines-against-SARS-CoV-2-Omicron-and-Delta-variants.aspx. (accessed May 28, 2024).

  • Harvard

    Sai Lomte, Tarun. 2023. Exploring the comparative efficacy of booster vaccines against SARS-CoV-2 Omicron and Delta variants. News-Medical, viewed 28 May 2024, https://www.news-medical.net/news/20220204/Exploring-the-comparative-efficacy-of-booster-vaccines-against-SARS-CoV-2-Omicron-and-Delta-variants.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New SARS-CoV-2 KP.2 variant defies vaccines with higher spread, study warns